Galectin Therapeutics Inc.

GALT Healthcare Biotechnology

In the quarter to June 2026, EPS fell 16.7%, free cash flow grew 63.1% and total debt fell 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.62 0.09 −2.43%
Market cap
$374.2M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
21.69% 21.41% 26.51% 33.96%

+8 more TTM periods

ROA
(184.22%) (209.09%) (167.30%) (178.99%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
20.46% (315.31%) (271.56%) 30.26%
Free Cash Flow per Share
(0.24) (0.30) (0.37) (0.48)
Free Cash Flow
(15.89) (20.05) (23.87) (30.62)
Other line items
Cash ROIC
83.96% (102.39%) (94.52%) 137.32%
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Interest Coverage
(2.02) (2.15) (2.74) (4.10)
Operating CF/Net income
0.57 0.76 0.77 0.82
Depreciation/Fixed assets
0.00 0.00 0.00 0.00
Capex/Depreciation
0.00 0.00 0.00 0.00
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.24) (0.30) (0.37) (0.48)
Capex per Share
0.00 0.00 0.00 0.00

Fold the line items

Columns are period end dates